September 18, 2017
The Angelman Syndrome Foundation is issuing the following statement regarding healthcare legislation in the US because of its impacts on the lives of people with Angelman syndrome and their families. Statement from Angelman Syndrome Foundation Board of Directors: The healthcare […]
Read more
August 14, 2017
See the paper by Matthew Judson in The Journal of Neuroscience. Summary Many individuals with Angelman syndrome (AS) have microcephaly—a smaller head and brain size—than typically developing individuals. This microcephaly is not present at birth, but becomes evident sometime during the […]
Read more
June 22, 2017
Angelman Biomarkers and Outcome Measures Alliance and Roche begin patient-centered qualitative research to inform potential outcome measures for Angelman syndrome clinical trials Nashville, Tenn. (June 22, 2017) – A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has […]
Read more
May 11, 2017
ASF-funded Research Identifies Biomarker for Clinical Trials ASF-funded research published in the Journal of Neurodevelopmental Disorders has identified that delta—a frequency of brain rhythms identifiable by EEG scans—can serve as a reliable biomarker for pre-clinical and clinical trials in Angelman syndrome. The research team, […]
Read more
April 24, 2017
Stem Cells Help UConn Researchers Identify Defects Causing Angelman syndrome Researchers at UConn Health are using stem cells derived from patients with Angelman syndrome to identify the underlying cellular defects that cause the rare neurogenetic disorder, an important step in […]
Read more
September 9, 2016
Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. See the press release.
Read more
April 20, 2016
Research has answered some questions about UBE3A’s role in seizures ASF-funded research conducted at Dr. Ben Philpot’s lab at the University of North Carolina-Chapel Hill has answered some questions about UBE3A’s role in seizures in individuals with Angelman syndrome, and […]
Read more
November 30, 2015
The ASF Celebrates the Opening of the New Angelman Syndrome Clinic at Mayo Clinic One-Stop Facility Provides Comprehensive Support for Individuals with Angelman syndrome from Infancy through Adulthood ROCHESTER, Minn., November 30, 2015 – Mayo Clinic and the Angelman Syndrome Foundation […]
Read more